# NOVA1

## Overview
NOVA1 is a gene that encodes the NOVA alternative splicing regulator 1, a neuron-specific RNA-binding protein that plays a pivotal role in the regulation of alternative splicing. This protein is characterized by its three K-homology (KH) domains, which are essential for its RNA-binding capabilities. NOVA1 is primarily expressed in the central nervous system and pancreatic beta cells, where it influences critical cellular processes such as synaptic plasticity, neurogenesis, and insulin secretion. The protein's ability to bind specific RNA sequences, such as UCAU and UCAY, allows it to regulate the splicing of pre-mRNA transcripts, impacting neuronal viability and function. NOVA1's involvement in various cellular pathways underscores its significance in both normal physiological processes and disease states, including neurological disorders and cancers (Buckanovich1996The; Villate2014Nova1; Meldolesi2020Alternative).

## Structure
The NOVA1 protein is characterized by its three K-homology (KH) domains, which are crucial for its RNA-binding function. These domains are approximately 70 amino acids long and contain a conserved hydrophobic core and a Gly-X-X-Gly motif, which are essential for maintaining the structural integrity of the protein (Jensen2000The; Lewis1999Crystal). The KH domains in NOVA1 form a compact, protease-resistant structure resembling an open-faced sandwich, consisting of a three-stranded antiparallel β sheet topped by three α helices (Lewis1999Crystal). The third KH domain (KH3) is particularly important for RNA binding, recognizing specific RNA sequences such as the tetranucleotide UCAY (Jensen2000The).

The tertiary structure of the KH3 domain has been elucidated through X-ray crystallography, revealing a three-dimensional α/β fold with dimensions of 15 Å × 25 Å × 30 Å (Lewis1999Crystal). The KH3 domain can form tetramers, with potential dimer interfaces that may be biologically relevant (Lewis1999Crystal). The protein is neuron-specific and expressed in the central nervous system, with its activity potentially influenced by post-translational modifications such as phosphorylation (Buckanovich1996The). NOVA1 also has splice variant isoforms, which may affect its function and localization.

## Function
NOVA1 (NOVA alternative splicing regulator 1) is a critical RNA-binding protein involved in the regulation of alternative splicing, primarily in neurons and pancreatic beta cells. In neurons, NOVA1 binds to specific RNA sequences, such as UCAU repeats, to regulate the splicing of pre-mRNA transcripts. This regulation is essential for neuronal viability and function, influencing processes like synaptic plasticity and neurogenesis. NOVA1's role in neurons includes the splicing of inhibitory receptor pre-mRNAs, such as GlyRα2, which is crucial for proper motor function and neuronal health (Buckanovich1997The; Jensen2000Nova1).

In pancreatic beta cells, NOVA1 acts as a master regulator of alternative splicing, affecting the splicing of nearly 5000 transcripts. It modulates pathways related to exocytosis, calcium signaling, and insulin secretion. NOVA1 influences the splicing of genes like PLCβ1 and SNAP-25, which are involved in insulin exocytosis, thereby playing a significant role in insulin release and beta cell viability. Its knockdown leads to decreased insulin secretion and increased apoptosis, highlighting its importance in maintaining beta cell function (Villate2014Nova1). NOVA1's activity in these cells underscores its broader impact on cellular signaling pathways and organismal outcomes.

## Clinical Significance
Mutations and alterations in the expression of the NOVA1 gene have been implicated in several neurological disorders and cancers. NOVA1 was initially identified in the context of paraneoplastic opsoclonus-myoclonus ataxia, a rare neurological disorder, where it plays a critical role in neuron-specific alternative splicing (Jensen2000Nova1). In amyotrophic lateral sclerosis (ALS), NOVA1's function in alternative splicing is disrupted, contributing to disease pathology. Studies have shown that NOVA1 exhibits both gain and loss-of-function features in ALS, with increased expression levels in early stages of the disease (Krach2022Aberrant). 

In cancer, NOVA1 expression varies across different tumor types. In astrocytoma, high NOVA1 expression is associated with poor survival outcomes, while in gastric cancer, its downregulation correlates with poor prognosis (Xin2017Neuro‐oncological). NOVA1 also interacts with microRNAs, influencing its role in oncogenesis. For instance, in glioblastoma and breast cancer, NOVA1 inhibits protective miRNAs, promoting cancer cell proliferation (Meldolesi2020Alternative). These findings highlight NOVA1's potential as a therapeutic target and prognostic biomarker in both neurological diseases and cancers.

## Interactions
NOVA1, a neuron-specific RNA-binding protein, is involved in several interactions with both proteins and nucleic acids. It is known to bind specific RNA sequences, particularly pyrimidine-rich motifs, which are crucial for its role in regulating alternative splicing. The KH3 domain of NOVA1 is essential for its high-affinity binding to RNA, specifically recognizing sequences such as UCAU and UCAY within RNA hairpin structures (Buckanovich1997The; Jensen2000The).

NOVA1 interacts with pre-mRNAs, including those encoding the inhibitory glycine receptor α2 (GlyR α2) and its own pre-mRNA, suggesting a role in autoregulation (Buckanovich1997The). The interaction with GlyR α2 pre-mRNA is significant, as it can be disrupted by antibodies from patients with paraneoplastic opsoclonus-myoclonus ataxia (POMA), indicating a potential link to motor dysfunction in this disorder (Buckanovich1997The).

In the context of amyotrophic lateral sclerosis (ALS), NOVA1 interacts with the proline–arginine dipeptide repeat protein (PR-DPR), which affects its function in splicing regulation. This interaction leads to the inclusion of cryptic exons in UNC13A mRNA, reducing UNC13A protein expression, a process that can be modulated by betulin treatment (Fu2023Interaction).


## References


[1. (Jensen2000Nova1) Kirk B Jensen, B.Kate Dredge, Giovanni Stefani, Ru Zhong, Ronald J Buckanovich, Hirotaka J Okano, Yolanda Y.L Yang, and Robert B Darnell. Nova-1 regulates neuron-specific alternative splicing and is essential for neuronal viability. Neuron, 25(2):359–371, February 2000. URL: http://dx.doi.org/10.1016/s0896-6273(00)80900-9, doi:10.1016/s0896-6273(00)80900-9. This article has 328 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/s0896-6273(00)80900-9)

[2. (Meldolesi2020Alternative) Jacopo Meldolesi. Alternative splicing by nova factors: from gene expression to cell physiology and pathology. International Journal of Molecular Sciences, 21(11):3941, May 2020. URL: http://dx.doi.org/10.3390/ijms21113941, doi:10.3390/ijms21113941. This article has 24 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms21113941)

[3. (Fu2023Interaction) Ru-Huei Fu, Hui-Jye Chen, and Syuan-Yu Hong. Interaction of the c9orf72-amyotrophic lateral sclerosis-related proline–arginine dipeptide repeat protein with the rna-binding protein nova1 causes decreased expression of unc13a due to enhanced inclusion of cryptic exons, which is reversed by betulin treatment. Cells, 12(20):2476, October 2023. URL: http://dx.doi.org/10.3390/cells12202476, doi:10.3390/cells12202476. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cells12202476)

[4. (Buckanovich1997The) Ronald J. Buckanovich and Robert B. Darnell. The neuronal rna binding protein nova-1 recognizes specific rna targets in vitro and in vivo. Molecular and Cellular Biology, 17(6):3194–3201, June 1997. URL: http://dx.doi.org/10.1128/MCB.17.6.3194, doi:10.1128/mcb.17.6.3194. This article has 337 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/MCB.17.6.3194)

[5. (Buckanovich1996The) RJ Buckanovich, YY Yang, and RB Darnell. The onconeural antigen nova-1 is a neuron-specific rna-binding protein, the activity of which is inhibited by paraneoplastic antibodies. The Journal of Neuroscience, 16(3):1114–1122, February 1996. URL: http://dx.doi.org/10.1523/jneurosci.16-03-01114.1996, doi:10.1523/jneurosci.16-03-01114.1996. This article has 144 citations.](https://doi.org/10.1523/jneurosci.16-03-01114.1996)

[6. (Villate2014Nova1) Olatz Villate, Jean-Valery Turatsinze, Loriana G. Mascali, Fabio A. Grieco, Tatiane C. Nogueira, Daniel A. Cunha, Tarlliza R. Nardelli, Michael Sammeth, Vishal A. Salunkhe, Jonathan L. S. Esguerra, Lena Eliasson, Lorella Marselli, Piero Marchetti, and Decio L. Eizirik. Nova1 is a master regulator of alternative splicing in pancreatic beta cells. Nucleic Acids Research, 42(18):11818–11830, September 2014. URL: http://dx.doi.org/10.1093/nar/gku861, doi:10.1093/nar/gku861. This article has 84 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1093/nar/gku861)

[7. (Xin2017Neuro‐oncological) Yu Xin, Zheng Li, Heyi Zheng, Jeffery Ho, Matthew T. V. Chan, and William K. K. Wu. Neuro‐oncological ventral antigen 1 (<scp>nova</scp>1): implications in neurological diseases and cancers. Cell Proliferation, April 2017. URL: http://dx.doi.org/10.1111/cpr.12348, doi:10.1111/cpr.12348. This article has 21 citations and is from a peer-reviewed journal.](https://doi.org/10.1111/cpr.12348)

[8. (Jensen2000The) Kirk B. Jensen, Kiran Musunuru, Hal A. Lewis, Stephen K. Burley, and Robert B. Darnell. The tetranucleotide ucay directs the specific recognition of rna by the nova k-homology 3 domain. Proceedings of the National Academy of Sciences, 97(11):5740–5745, May 2000. URL: http://dx.doi.org/10.1073/pnas.090553997, doi:10.1073/pnas.090553997. This article has 114 citations.](https://doi.org/10.1073/pnas.090553997)

[9. (Lewis1999Crystal) Hal A Lewis, Hua Chen, Carme Edo, Ronald J Buckanovich, Yolanda YL Yang, Kiran Musunuru, Ru Zhong, Robert B Darnell, and Stephen K Burley. Crystal structures of nova-1 and nova-2 k-homology rna-binding domains. Structure, 7(2):191–203, February 1999. URL: http://dx.doi.org/10.1016/s0969-2126(99)80025-2, doi:10.1016/s0969-2126(99)80025-2. This article has 85 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/s0969-2126(99)80025-2)

[10. (Krach2022Aberrant) Florian Krach, Emily C. Wheeler, Martin Regensburger, Tom Boerstler, Holger Wend, Anthony Q. Vu, Ruth Wang, Stephanie Reischl, Karsten Boldt, Ranjan Batra, Stefan Aigner, John Ravits, Juergen Winkler, Gene W. Yeo, and Beate Winner. Aberrant nova1 function disrupts alternative splicing in early stages of amyotrophic lateral sclerosis. Acta Neuropathologica, 144(3):413–435, July 2022. URL: http://dx.doi.org/10.1007/s00401-022-02450-3, doi:10.1007/s00401-022-02450-3. This article has 12 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1007/s00401-022-02450-3)